| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 60 |
| 1 | BEVACIZUMAB | 41 |
| 2 | CAPECITABINE | 38 |
| 3 | FLUOROURACIL | 22 |
| 4 | FLUOROURACIL CREAM, 0.5% | 22 |
| 5 | IRINOTECAN HYDROCHLORIDE | 9 |
| 6 | LEUCOVORIN CALCIUM | 7 |
| 7 | LEVOLEUCOVORIN | 4 |
| 8 | LEVOLEUCOVORIN CALCIUM | 4 |
| 9 | LEVOLEUCOVORIN INJECTION | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LEVOLEUCOVORIN INJECTION | 4 | 0.0013 |
| 1 | LEVOLEUCOVORIN | 4 | 0.0010 |
| 2 | OXALIPLATIN | 60 | 0.0008 |
| 3 | IRINOTECAN HYDROCHLORIDE | 9 | 0.0007 |
| 4 | CAPECITABINE | 38 | 0.0004 |
| 5 | LEUCOVORIN CALCIUM | 7 | 0.0004 |
| 6 | DANAZOL | 1 | 0.0004 |
| 7 | IOPAMIDOL | 1 | 0.0003 |
| 8 | BEVACIZUMAB | 41 | 0.0003 |
| 9 | FLUOROURACIL CREAM, 0.5% | 22 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 41 | 0.0002 |
| 1 | Platinum-based Drug [EPC] | 60 | 0.0002 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 51 | 0.0002 |
| 3 | Somatostatin Analog [EPC] | 1 | 0.0001 |
| 4 | Epidermal Growth Factor Receptor Antagonist [EPC] | 5 | 0.0001 |
| 5 | Antifibrinolytic Agent [EPC] | 1 | 0.0001 |
| 6 | GLP-2 Analog [EPC] | 1 | 0.0001 |
| 7 | Nucleoside Analog Antiviral [EPC] | 4 | 0.0000 |
| 8 | Radiographic Contrast Agent [EPC] | 1 | 0.0000 |
| 9 | Androgen [EPC] | 1 | 0.0000 |